23 results
Thumbnail

D2.378 - Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule

Thumbnail

D2.367 - Hepatic Involvement and Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Retrospective Evaluation

Thumbnail

D2.368 - Concurrent Hereditary Angioedema Type I and Common Variable Immunodeficiency Presenting as Suspected Antibiotic Hypersensitivity: Case Report and Literature Review

Thumbnail

D2.370 - Chronic urticaria and autoimmunity: clinical, laboratory and molecular correlations

Thumbnail

D2.374 - Diagnostic delay in children with primary immunodeficiencies: clinical consequences in a single-country cohort from the Republic of Moldova

Thumbnail

D2.375 - Structural lung changes detected by chest CT in pediatric patients with combined immunodeficiencies

Thumbnail

D2.377 - Severe Eosinophilia as an Atypical Initial Presentation of X-Linked Hyper-IgM Syndrome Due to CD40LG Deficiency

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD

Thumbnail

D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis

Thumbnail

- D3.519 - Post-COVID-19 Reshaping of Molecular IgE Sensitization Profiles to Seasonal and Indoor Allergens

Thumbnail

D3.521 - Dermatologic adverse effects of COVID-19 vaccination

Thumbnail

- D3.522 - Post-Vaccination SARS-CoV-2 Infections: Evidence, Severity, and Outcomes

Thumbnail

D3.523 - Early childhood: a risk predictor for post-COVID-19 pulmonary sequelae in children

Thumbnail

- D3.524 - Clinical use of procalcitonin and IL-6 in diagnosis of bacterial superinfection in COVID-19